© 2000 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
Quality of Life in Schizophrenia: A Comparison of Instruments
Members of the VA Connecticut Healthcare System, West Haven, CT, and of the Yale University School of Medicine, Department of Psychiatry New Haven, CT
Members of the VA Cooperative Studies Program Coordinating Center, Hines, IL. All are members of the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia
Send reprint requests to Ms. J.A. Cramer, VA Connecticut Healthcare System (G7E), 950 Campbell Ave., West Haven, CT 06516-2770; e-mail: joyce.cramer{at}yale.edu
Health-related quality of life in schizophrenia can be assessed by direct patient response or by a rating based on a structured interview. This study compares both types of instruments using a series of five standards: (1) sensitivity to change over time, (2) sensitivity to treatment effect, (3) correlation with symptom severity, (4) correlation with global clinical ratings, and (5) correlation with other measures of health-related quality of life. Four hundred and twenty-three inpatients with schizophrenia participating in a clinical trial comparing clozapine and haloperidol (VA Cooperative Study in Health Services #17) were evaluated using multiple measures of health-related quality of life (Lehman Quality of Life Interview; Heinrichs Carpenter-Hanlon Quality of Life Scale; Strauss-Carpenter Level of Function scale, and clinical response.) The Quality of Life Interview showed less sensitivity to change and treatment effect, as well as lower correlations with all other measures than the Quality of Life Scale and the Level of Function scale. The latter scales showed high sensitivity to both change and treatment effect, and moderate-high correlations with other measures and with each other. The Quality of Life Scale and the Level of Function scale rater assessments appeared to be substantially more sensitive to subtle change and treatment effects than the patient-reported Quality of Life Interview for clinical trials. Health-related quality of life in schizophrenia is a more heterogeneous concept than previously appreciated.
Keywords: Schizophrenia / quality of life / clinical trial / functional status / symptoms
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup, and J. A. Lieberman Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia Schizophr Bull, March 1, 2009; 35(2): 336 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mohamed, R. Rosenheck, M. Swartz, S. Stroup, J. A. Lieberman, and R. S.E. Keefe Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 978 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Matza, R. Buchanan, S. Purdon, J. Brewster-Jordan, Y. Zhao, and D. A. Revicki Measuring Changes in Functional Status Among Patients With Schizophrenia: The Link With Cognitive Impairment Schizophr Bull, October 1, 2006; 32(4): 666 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Jones, T. R. E. Barnes, L. Davies, G. Dunn, H. Lloyd, K. P. Hayhurst, R. M. Murray, A. Markwick, and S. W. Lewis Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, October 1, 2006; 63(10): 1079 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Burlingame, T. W. Dunn, S. Chen, A. Lehman, R. Axman, D. Earnshaw, and F. M. Rees Special Section on the GAF: Selection of Outcome Assessment Instruments for Inpatients With Severe and Persistent Mental Illness Psychiatr Serv, April 1, 2005; 56(4): 444 - 451. [Abstract] [Full Text] [PDF]
|
|